Incyte Corporation


Incyte, MorphoSys Win FDA Nod For ‘Key Revenue Driver’ Tafasitamab

Incyte (INCY) and MorphoSys (MOR) have announced that the US Food and Drug Administration (FDA) has approved Monjuvi (tafasitamab-cxix) plus lenalidomide for adults with relapsed …

Incyte’s Bile Duct Cancer Drug Wins FDA Approval

Incyte (INCY) has announced that the FDA has approved Pemazyre, a kinase inhibitor for the treatment of adults with unresectable cholangiocarcinoma, a rare cancer …

Incyte to Trial Cancer Drug for Patients with COVID-19 Associated Cytokine Storm

Global biopharma Incyte (INCY) has announced plans to initiate a Phase 3 clinical trial to evaluate cancer drug Jakafi in patients with COVID-19 …

Incyte Corporation (INCY) Shares Tumble on FDA Setback for Rheumatoid Arthritis Drug

Incyte Corporation (NASDAQ:INCY) investors are heading for the hills, after the drug maker, along with its partner Eli Lilly (NYSE:LLY), announced that the FDA issued …

Company Update (NASDAQ:INCY): Incyte Corporation and Eli Lilly Announce FDA Extension of Review Period for Baricitinib NDA

Incyte Corporation (NASDAQ:INCY) and Eli Lilly and Co (NYSE:LLY) announced that the U.S.

This Top Analyst Sees Incyte Corporation (INCY) Shares Have Significant Upside Ahead

After Incyte Corporation (NASDAQ:INCY) announced positive clinical pipeline updates that had investors celebrating and shares soaring 9%, top analyst Eric Schmidt at Cowen …

Company Update (NASDAQ:INCY): Here’s Why Incyte Corporation Shares Are Rising 7% Today

Incyte Corporation (NASDAQ: INCY) and Merck (NYSE:MRK) announced the decision to advance the clinical development program investigating the combination of epacadostat, Incyte’s investigational oral …

Company Update (NASDAQ:INCY): Incyte Corporation and Merus NV Announce Global Strategic Research Collaboration to Discover and Develop Bispecific Antibodies

Incyte Corporation (NASDAQ:INCY) and Merus NV (NASDAQ:MRUS) announced today that they have entered into a global, strategic collaboration agreement focused on the research, …

Company Update (NASDAQ:INCY): CHMP Recommends Approval of Incyte Corporation and Eli Lilly and Co’s Baricitinib for the Treatment of Active Rheumatoid Arthritis (RA)

Incyte Corporation (NASDAQ:INCY) and Eli Lilly and Co (NYSE:LLY) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human …

Stock Update (NASDAQ:INCY): Incyte Corporation Announces New Data Analyses of Two Phase 3 Trials in Rheumatoid Arthritis

Incyte Corporation (NASDAQ:INCY) and Eli Lilly and Company (NYSE:LLY) announced new data analyses of two phase 3 trials, RA-BUILD and RA-BEAM, showing that …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts